Hepatocellular carcinoma
Conditions
Interventions
Experimental group:Combined intervention of PD-1 mAb + lovastatin + TACE
Control group:TACE intervention alone
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 75 years old; 2) There was no history of serious arrhythmia and heart failure. 3) There was no history of severe ventilation dysfunction and severe pulmonary infection. 4) There was no acute or chronic renal failure. The creatinine clearance rate was more than 40 ml / min. 5) Good liver function: child Pugh grade A or B (= 28 g/L, AST, alt, ALP =1.5x10^9/L, Hb >=8.5 g/L, PLT >=75x10^9/L (no blood transfusion and drug treatment correction within 14 days before screening); 7) Coagulation function INR < = 2.3; 8) The pathological results were hepatocellular carcinoma (HCC); 9) Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) Those who have suffered from or are suffering from other malignant tumors; 3) Recurrent hepatocellular carcinoma; 4) Patients with mental illness were combined; 5) It is estimated that targeted drugs such as PD-1 monoclonal antibody sorafenib may be used after surgery; 6) Human immunodeficiency virus (HIV) carriers; 7) Patients with unresectable liver cancer or liver cancer who need liver transplantation; 8) Advanced hepatocellular carcinoma with systemic metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival;CD4+ / CD8+ ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;time to recurrence; | — |
Countries
China
Contacts
Public ContactTao Yifeng
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed